Found 9 of ic50 for monomerid = 311600 TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.900nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.900nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.900nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 1.90nMAssay Description:RET (V804M) (i.e., RET with V804M mutation) kinase activity was measured using purified recombinant human RET (V804M) protein purchased from Eurofins...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 1.90nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 1.90nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
